医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Clinical Safety Innovator, Flat Medical, Secured Series B Financing for Global Development

2020年01月23日 PM09:30
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan

Flat Medical Co., Ltd., a Medtech company specializing in clinical safety solutions, announced that it has secured Series B funding today, to extend their innovative product portfolio and global business growth.

Led by the National Development Fund, a strategic fund managed by the National Development Council of Taiwan, the round was also participated by several individual investors and existing shareholders, including Acorn Campus Taiwan and The Everjuan Enterprise Co., Ltd.

“Safety improvement in anesthesia and critical care is a real need,” said Dr. Michel Chu, a general partner at Acorn Campus Taiwan. “We have worked with the Flat Medical team for several years, and have strong confidence in their ability to execute on its goal of eliminating clinical risks.”

After acquiring CE mark and FDA clearance for its first product, EpiFaith®, in 2019, Flat Medical has presented the epidural safeguard in worldwide anesthesia communities and started trials in selected leading university hospitals in the U.S. and Europe. “We received a lot of great feedback and inquiries in the past two quarters, and realized that it’s time for us to prepare for the upcoming leap,” said Dr. Joseph Luo, CEO of Flat Medical. “This funding fuels us to accelerate our business development and product pipeline extension. We appreciate the investment from our long-term supporters and the government.”

Besides the active presence of the well-known epidural safety product, EpiFaith®, the company is now developing a central line safety product, EpiFaith® CV, striving to eradicate the risks in anesthesia and critical care units. The EpiFaith® CV is expected to launch in the U.S. and Europe in early 2021.

About Flat Medical Co., Ltd.

Flat Medical is a Medtech company focusing on safety solutions for clinical procedures. Supported by key opinion leaders and venture capitalists in the United States, Europe, and Asia, the company is commercializing and developing different applications for its innovative EpiFaith® tech.

About Acorn Campus Taiwan

With headquarters in Santa Clara and Taipei, Acorn Campus Taiwan is an active venture capital firm that focuses on working with early-stage and mid-stage life science and technology startups across the Pacific Ocean.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005267/en/

CONTACT

Media:

Karl Tsao

karltsao@flatmedical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Coronavirus IS a Pandemic — WHO, Declare It Now!
  • Hot Topics Recap: Coronavirus
  • Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
  • Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
  • CGTN: How China Mobilizes Whole Country to Contain Coronavirus Disease 2019 (COVID-19)